467 related articles for article (PubMed ID: 26369753)
1. Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation.
Evans RA; Clifford TM; Tang S; Au T; Fugit AM
Transpl Infect Dis; 2015 Dec; 17(6):816-21. PubMed ID: 26369753
[TBL] [Abstract][Full Text] [Related]
2. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis.
Souza JP; Boeckh M; Gooley TA; Flowers ME; Crawford SW
Clin Infect Dis; 1999 Dec; 29(6):1467-71. PubMed ID: 10585797
[TBL] [Abstract][Full Text] [Related]
3. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation.
Gabardi S; Millen P; Hurwitz S; Martin S; Roberts K; Chandraker A
Clin Transplant; 2012; 26(3):E184-90. PubMed ID: 22487221
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
[TBL] [Abstract][Full Text] [Related]
5. Lower risk of urinary tract infection with low-dose trimethoprim/sulfamethoxazole compared to dapsone prophylaxis in older renal transplant patients on a rapid steroid-withdrawal immunosuppression regimen.
Giullian JA; Cavanaugh K; Schaefer H
Clin Transplant; 2010; 24(5):636-42. PubMed ID: 19925478
[TBL] [Abstract][Full Text] [Related]
6. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
Warnock AC; Rimland D
Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
[TBL] [Abstract][Full Text] [Related]
7. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Urbancic KF; Pisasale D; Wight J; Trubiano JA
Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past.
Wang EH; Partovi N; Levy RD; Shapiro RJ; Yoshida EM; Greanya ED
Transpl Infect Dis; 2012 Oct; 14(5):519-25. PubMed ID: 22571389
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
[TBL] [Abstract][Full Text] [Related]
11. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole.
Beumont MG; Graziani A; Ubel PA; MacGregor RR
Am J Med; 1996 Jun; 100(6):611-6. PubMed ID: 8678080
[TBL] [Abstract][Full Text] [Related]
12. Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia.
Barber BA; Pegram PS; High KP
Clin Infect Dis; 1996 Oct; 23(4):718-22. PubMed ID: 8909833
[TBL] [Abstract][Full Text] [Related]
13. Absence of Pneumocystis jiroveci pneumonia in liver transplantation recipients receiving short-term (3-month) prophylaxis.
Trotter JF; Levi M; Steinberg T; Lancaster J
Transpl Infect Dis; 2008 Oct; 10(5):369-71. PubMed ID: 18482201
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.
Hughes WT
Antimicrob Agents Chemother; 1988 May; 32(5):623-5. PubMed ID: 3260765
[TBL] [Abstract][Full Text] [Related]
15. Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients.
Saukkonen K; Garland R; Koziel H
Chest; 1996 May; 109(5):1250-5. PubMed ID: 8625676
[TBL] [Abstract][Full Text] [Related]
16. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
17. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
[TBL] [Abstract][Full Text] [Related]
18. Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.
Simonds RJ; Hughes WT; Feinberg J; Navin TR
Clin Infect Dis; 1995 Aug; 21 Suppl 1():S44-8. PubMed ID: 8547511
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis.
de Boer MG; Kroon FP; le Cessie S; de Fijter JW; van Dissel JT
Transpl Infect Dis; 2011 Dec; 13(6):559-69. PubMed ID: 21689251
[TBL] [Abstract][Full Text] [Related]
20. Pneumocystis jirovecii pneumonia in renal transplant recipients: a national center experience.
Borstnar S; Lindic J; Tomazic J; Kandus A; Pikelj A; Prah J; Skvarc M; Godnov U; Kovac D
Transplant Proc; 2013 May; 45(4):1614-7. PubMed ID: 23726632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
